Guardant Health CFO sells shares, exercises RSUs

Guardant Health, Inc. Chief Financial Officer Michael Brian Bell reported a mix of equity compensation vesting and share dispositions.

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Financial Officer Michael Brian Bell reported a mix of equity compensation vesting and share dispositions. On March 15, 2026, restricted stock units and performance-based restricted stock units covering a total of 13,790 shares of Common Stock vested and were converted at a $0.0000 exercise price. To satisfy tax obligations on this vesting, 7,413 shares were withheld by the company at a price of $85.4900 per share. On March 16, 2026, Bell completed an open-market sale of 3,000 shares of Common Stock at a weighted average price of $87.0370 per share. After these transactions, he directly holds 43,601 shares of Guardant Health Common Stock.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 8 txns

Insider Bell Michael Brian

Role Chief Financial Officer

Sold 3,000 shs ($261K)

Approx. gross sale proceeds $261K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$87.037	$261K
Exercise	Restricted Stock Units	1,233	$0.00	$0.00
Exercise	Performance-Based Restricted Stock Units	10,518	$0.00	$0.00
Exercise	Restricted Stock Units	2,039	$0.00	$0.00
Exercise	Common Stock	1,233	$0.00	$0.00
Exercise	Common Stock	10,518	$0.00	$0.00
Exercise	Common Stock	2,039	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	7,413	$85.49	$634K

Holdings After Transaction: Restricted Stock Units — 2,039 contracts (Direct); Performance-Based Restricted Stock Units — 0 contracts (Direct); Common Stock — 43,601 shares (Direct)

Footnotes (6)

1. F1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
2. F2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.0001 to $87.1500. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. This represents a restricted stock unit award granted on May 9, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on March 15, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter.
4. F4. Not applicable for Restricted Stock Units.
5. F5. This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026.
6. F6. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Guardant Health (GH) CFO Michael Brian Bell report?

Michael Brian Bell reported vesting of restricted and performance-based stock units converting into 13,790 Guardant Health common shares, tax withholding using 7,413 shares, and an open-market sale of 3,000 shares. These actions reflect routine equity compensation events combined with a modest share disposition.

How many Guardant Health (GH) shares did the CFO sell and at what price?

The CFO sold 3,000 shares of Guardant Health Common Stock in an open-market transaction at a weighted average price of $87.0370 per share. The shares were sold in multiple trades between $87.0001 and $87.1500, as disclosed in the footnotes to the filing.

What RSU and performance-based RSU awards vested for Guardant Health (GH) CFO?

The filing shows 1,233 restricted stock units and 10,518 performance-based restricted stock units converting into Guardant Health Common Stock on March 15, 2026. These awards stem from grants made in 2022 and 2023, with vesting tied to multi-year service and performance conditions detailed in the footnotes.

How many Guardant Health (GH) shares does the CFO hold after these transactions?

Following the reported vesting, tax withholding, and stock sale, Michael Brian Bell directly owns 43,601 shares of Guardant Health Common Stock. This figure reflects his remaining position after the 7,413-share tax withholding and the 3,000-share open-market sale disclosed in the Form 4.

Why were some Guardant Health (GH) shares withheld in the CFO’s Form 4 filing?

The company retained 7,413 Guardant Health shares to meet the CFO’s tax withholding obligations arising from RSU vesting. According to the footnote, the retained amount did not exceed the associated tax liability, indicating a standard share-withholding mechanism rather than an open-market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 06:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bell Michael Brian

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		1,233	A	$0	41,457	D
Common Stock	03/15/2026		M		10,518	A	$0	51,975	D
Common Stock	03/15/2026		M		2,039	A	$0	54,014	D
Common Stock	03/15/2026		F		7,413(1)	D	$85.49	46,601	D
Common Stock	03/16/2026		S		3,000	D	$87.037(2)	43,601	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/15/2026		M			1,233	(3)	(4)	Common Stock	1,233	$0	0	D
Performance-Based Restricted Stock Units	$0	03/15/2026		M			10,518	(5)	(4)	Common Stock	10,518	$0	0	D
Restricted Stock Units	$0	03/15/2026		M			2,039	(6)	(4)	Common Stock	2,039	$0	2,039	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.0001 to $87.1500. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. This represents a restricted stock unit award granted on May 9, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on March 15, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter.

4. Not applicable for Restricted Stock Units.

5. This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026.

6. This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Michael Brian Bell	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.